Over the past decade, generics companies have saved the US healthcare system over $1.2 trillion. Globally, generics companies continue to reduce the cost of medicines while also increasing access to life-saving medications. Particularly over the past year, the first biosimilar was introduced in the US, GDUFA was reauthorized, mergers and acquisitions surged, and pricing became a hot-button issue. As such, generics companies have an opportunity to demonstrate their adaptability and ingenuity, as well as the value they bring to the healthcare system.
To read the 2016 Generics Industry Trends report, click on the PDF below.